Investment
Features
FeesSafety
Academy
More
Pluang+

FDA review of compounded peptides could reshape Hims & Hers' growth outlook and valuation.

Market News
16 Apr 2026
Seeking Alpha
View Source
Neutral
pluang ai news

Hims & Hers faces a critical regulatory review as the FDA reconsiders compounded peptide therapies, particularly GLP-1 drugs like semaglutide. A favorable FDA stance could validate these therapies, boosting Hims & Hers' growth prospects and narrowing its current revenue multiple discount compared to peers. However, stricter regulations might remove a key growth driver, increasing the company's regulatory risk and maintaining its valuation discount. The FDA's upcoming advisory meetings in July will be pivotal for the company's future trajectory.

More News (HIMS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App